Beyond post-marketing research and MedWatch: Long-term studies of ...
First, since companies are not required to publish the results of their post- marketing research, they could decide to suppress results that demonstrate the
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763348/...
|
Tuft's report backs FDA fast-track, but post-marketing concerns ...
A new report from the Center for the Study of Drug Development at Tufts ... in its development of the anti-cancer agent Xyotax (paclitaxel poliglumex). ... But
instead of withdrawing the agent from the market, the FDA limited its use to
patients who had already benefited from it. ... Clinical Practice & Research ...
http://www.nature.com/nbt/journal/v24/n5/full/nbt0506-478.ht...
|
Genentech: Medicines: Herceptin Development Timeline
1976, The research of Michael Bishop and Harold Varmus at the University of ... trial 648 to include paclitaxel chemotherapy as an alternative to doxorubicin
... exclusive marketing rights for Herceptin outside of the United States. ...
May 2000, Genentech issued a letter to healthcare providers about reports of ...
http://www.gene.com/gene/products/information/oncology/herce...
|
Industrial Uses of Agricultural Materials Situation and Outlook Report
market, and the competitiveness of other companies and joined. Though both procedures are ... ing research on its paclitaxel-like compound Taxotere. ...
http://www.ers.usda.gov/publications/IUS3/ius3f.pdf...
|
Modelling the market uptake of new drugs following listing for ...
Modelling the market uptake of new drugs following listing for subsidy in Australia. A report from the Drug Utilisation Subcommittee of the Australian ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1365162/...
|
Genentech: Investors: 2007 Annual Report
22 Feb 2008 ... While we are proud of the caliber of our internal research ... Our scientific accomplishments continue to translate into strong market success. ... Avastin in
combination with paclitaxel for the treatment of patients who ...
http://www.gene.com/gene/ir/financials/annual-reports/2007/e...
|
Abbott's XIENCE V® Approved in Japan – Second Largest Drug Eluting ...
8 Jan 2010 ... the risk of MACE compared to the TAXUS® Express2 Paclitaxel-Eluting Coronary ... thrombosis per the Academic Research Consortium (ARC) definition compared to
... Abbott's market-leading XIENCE V is used to treat coronary artery ... XIENCE
V is built upon Abbott's market-leading bare metal stent, ...
http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/P...
|
IRESSA (Gefitinib) Receives Marketing Authorisation for the ...
1 Jul 2009 ... Corporate reports · Facts, products, pipeline · Photo library ... In 2005, AstraZeneca withdrew its EU marketing authorisation application for IRESSA ...
safety and tolerability of IRESSA versus carboplatin/paclitaxel as ... engaged
in the research, development, manufacturing and marketing of ...
http://www.astrazeneca.com/media/latest-press-releases/2009/...
|
drug discovery@nature.com
ORIGINAL RESEARCH PAPER Fellner, S. et al. Transport of paclitaxel (Taxol) across the blood brain barrier in vitro and in vivo. J. Clin. Invest. ...
http://www.nature.com/drugdisc/res_high/articles/nrc961.html...
|
Ten years of marketing approvals of anticancer drugs in Europe ...
This report is based on the information available on the EMEA web site. ..... Lenfant C. Shattuck lecture – clinical research to clinical practice – lost ...
of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel,
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361592/...
|
